TY - JOUR
T1 - Primary Lateral Sclerosis Natural History Study
T2 - Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment
AU - for the PLS NHS Study Group
AU - Lee, Ikjae
AU - Jang, Grace
AU - Cheung, Ying Kuen
AU - Sherman, Alexander V.
AU - Johnston, Wendy S.
AU - Diaz, Frank
AU - Fernandes, J. Americo M.
AU - Habib, Ali A.
AU - Maragakis, Nicholas J.
AU - Paganoni, Sabrina
AU - Burke, Katherine
AU - Oskarsson, Bjorn
AU - Shah, Jaimin
AU - Zinman, Lorne
AU - Floeter, Mary Kay
AU - Ajroud-Driss, Senda
AU - Gwathmey, Kelly
AU - Heiman-Patterson, Terry
AU - Jawdat, Omar
AU - Kasarskis, Edward J.
AU - Kisanuki, Yaz Y.
AU - Wymer, James
AU - Fournier, Christina
AU - Hayat, Ghazala
AU - Heitzman, Daragh
AU - Lomen-Hoerth, Catherine
AU - Pulley, Michael T.
AU - Scelsa, Stephen N.
AU - Walk, David
AU - Goutman, Stephen A.
AU - Shoesmith, Christen
AU - Simmons, Zachary
AU - Sorenson, Eric
AU - Elman, Lauren
AU - Harms, Matthew B.
AU - Hoover, Benjamin N.
AU - Yun, Rebecca Y.
AU - Santella, Regina M.
AU - Mitsumoto, Hiroshi
N1 - Publisher Copyright:
© 2025 American Neurological Association.
PY - 2026/2
Y1 - 2026/2
N2 - Objective: The primary lateral sclerosis (PLS) consensus diagnostic criteria and functional rating scale (PLSFRS) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study (PLS NHS) to understand their performance in this prospective cohort. Methods: The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2–4 years); and definite PLS (4–15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3-, 6-, 9-, and 12-month follow-up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed-effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models. Results: A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS. Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27–0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year (p = 0.001). Interpretation: In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428.
AB - Objective: The primary lateral sclerosis (PLS) consensus diagnostic criteria and functional rating scale (PLSFRS) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study (PLS NHS) to understand their performance in this prospective cohort. Methods: The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2–4 years); and definite PLS (4–15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3-, 6-, 9-, and 12-month follow-up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed-effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models. Results: A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS. Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27–0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year (p = 0.001). Interpretation: In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428.
UR - https://www.scopus.com/pages/publications/105018475085
UR - https://www.scopus.com/pages/publications/105018475085#tab=citedBy
U2 - 10.1002/ana.78056
DO - 10.1002/ana.78056
M3 - Article
C2 - 41020440
AN - SCOPUS:105018475085
SN - 0364-5134
VL - 99
SP - 418
EP - 428
JO - Annals of Neurology
JF - Annals of Neurology
IS - 2
ER -